# The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

Study · id `cardio:ct-nct06236022` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06236022](<https://clinicaltrials.gov/study/NCT06236022>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06236022

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.

## Technical summary

Registry record NCT06236022. Randomized; no masking; primary purpose treatment. Start 2024-01-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 276 participants (planned count; ClinicalTrials.gov record NCT06236022, source copy `cardio:ctgov-nct06236022-2024-02-01`, retrieved 2026-10-31)
- Started: 2024-01-01 (actual) (ClinicalTrials.gov record NCT06236022, source copy `cardio:ctgov-nct06236022-2024-02-01`, retrieved 2026-10-31)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06236022, source copy `cardio:ctgov-nct06236022-2024-02-01`, retrieved 2026-10-31)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06236022, source copy `cardio:ctgov-nct06236022-2024-02-01`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06236022, source copy `cardio:ctgov-nct06236022-2024-02-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06236022-2024-02-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
- Acronym: SDCMK
- Condition: Dilated Cardiomyopathy
- Condition: Kaposi's Sarcoma-Associated Herpesvirus Infection
- Intervention (Drug): Sirolimus
- Lead sponsor: Tongji Hospital
- Lead sponsor class: OTHER
- Collaborator: Wuhan Central Hospital
- Collaborator class: OTHER
- Collaborator: Wuhan Fourth Hospital
- Collaborator class: OTHER
- Collaborator: Wuhan University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Dilated cardiomyopathy (`cardio:dilated-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Tongji Hospital (`cardio:org-tongji-hospital`)
- Registry lists this organization as a collaborator: Wuhan Central Hospital (`cardio:org-wuhan-central-hospital`)
- Registry lists this organization as a collaborator: Wuhan University (`cardio:org-wuhan-university`)

## Provenance

Content hash: 0bb226ea786b5a3d217d1df9d1136055be27033cf43d4bdf7d8a013f2364db22
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
